朱園飛,李改云,常豪,魚康康,高月求,鄧強
1. 上海中醫(yī)藥大學(xué)附屬曙光醫(yī)院細(xì)胞免疫實驗室,上海 201203; 2. 中國科學(xué)院上海巴斯德研究所分子病毒與免疫重點實驗室,上海 200032
·論著·
應(yīng)用微環(huán)DNA技術(shù)體外誘導(dǎo)和制備重組的乙型肝炎病毒共價閉合環(huán)狀DNA
朱園飛1, 2,李改云2,常豪2,魚康康2,高月求1,鄧強1, 2
1. 上海中醫(yī)藥大學(xué)附屬曙光醫(yī)院細(xì)胞免疫實驗室,上海 201203; 2. 中國科學(xué)院上海巴斯德研究所分子病毒與免疫重點實驗室,上海 200032
乙型肝炎病毒(hepatitis B virus,HBV)共價閉合環(huán)狀DNA(covalently closed circular DNA,cccDNA)是病毒慢性感染的分子基礎(chǔ)。本課題組前期研究通過Cre/loxP介導(dǎo)的位點特異性DNA重組策略,在細(xì)胞核內(nèi)由前體質(zhì)粒誘導(dǎo)重組cccDNA(rcccDNAloxP)產(chǎn)生,首次建立了HBV cccDNA的體外培養(yǎng)細(xì)胞和小鼠實驗?zāi)P?。本研究基于大腸埃希菌ZYCY10P3S2T PhiC31重組酶誘導(dǎo)表達系統(tǒng),建立了一種體外誘導(dǎo)HBV rcccDNA(rcccDNAattR)微環(huán)產(chǎn)生和純化的策略。純化的rcccDNAattR微環(huán)具有超螺旋結(jié)構(gòu),細(xì)胞培養(yǎng)實驗證實其能支持功能性的HBV復(fù)制和抗原表達。與普通的線性HBV復(fù)制子編碼質(zhì)粒相比,rcccDNAattR尾靜脈高壓注射小鼠模型能誘導(dǎo)顯著延長的病毒抗原血癥。因此,本研究在原核表達系統(tǒng)和實驗小鼠水平提供了一種更為簡化的HBV cccDNA實驗?zāi)P拖到y(tǒng),并再次顯示rcccDNA具有顯著的穩(wěn)定性,能作為一種基本策略在小鼠模型中誘導(dǎo)病毒持續(xù)感染。
微環(huán)DNA技術(shù);PhiC31;位點特異性重組;乙型肝炎病毒;共價閉合環(huán)狀DNA
乙型肝炎病毒(hepatitis B virus,HBV)成熟粒子中含有約3.2 kb的松弛環(huán)狀DNA基因組(relaxed circular DNA,rcDNA)。在病毒感染的肝細(xì)胞核內(nèi),rcDNA修復(fù)為共價閉合環(huán)狀DNA(covalently closed circular DNA, cccDNA),是HBV 轉(zhuǎn)錄復(fù)制的原始模板[1]。rcDNA修復(fù)生成的cccDNA具有超螺旋結(jié)構(gòu),能結(jié)合組蛋白等形成串珠樣核小體的微小染色體結(jié)構(gòu)[2],具有表觀遺傳學(xué)修飾特征[3]。細(xì)胞核cccDNA具有較長的代謝周期,且能通過細(xì)胞分裂傳遞至子代細(xì)胞。細(xì)胞凋亡或壞死是cccDNA體內(nèi)代謝的主要途徑[4]。cccDNA是HBV慢性感染的分子基礎(chǔ),現(xiàn)有抗病毒藥物可有效抑制病毒復(fù)制和rcDNA形成,但難以清除cccDNA,這是慢性乙型肝炎難以徹底治愈的主要原因[5-6]。
HBV感染的肝細(xì)胞中cccDNA拷貝數(shù)較低,迄今仍缺乏簡單、高效的技術(shù)方法用于研究。本課題組早先通過構(gòu)建含有線性單拷貝HBV基因組的編碼質(zhì)粒prcccDNA,在HBV基因組兩側(cè)引入同向loxP位點;在細(xì)胞核內(nèi),Cre重組酶引發(fā)loxP位點之間DNA 重組和環(huán)化,生成含有單拷貝loxP位點的rcccDNA;loxP位點則位于一段約90 bp的外源內(nèi)含子5′供體序列與3′受體序列之間,可在RNA轉(zhuǎn)錄過程中實現(xiàn)高效拼接[7]。應(yīng)用尾靜脈高壓技術(shù),共注射前體質(zhì)粒prcccDNA及Cre編碼質(zhì)粒,能在免疫功能健全小鼠中誘導(dǎo)顯著延長的HBV抗原血癥,可作為一種基本策略用于發(fā)展HBV持續(xù)感染和慢性肝炎的實驗小鼠模型[7]。
本研究報道了一種由PhiC31介導(dǎo)的位點特異性重組策略[8-9],在大腸埃希菌中誘導(dǎo)rcccDNA產(chǎn)生。由于系統(tǒng)中刪除了具有原核特征的質(zhì)粒骨架序列,應(yīng)用純化的rcccDNA尾靜脈高壓注射小鼠,可能僅激活有限的宿主免疫反應(yīng),所以能誘導(dǎo)顯著延長的HBV持續(xù)感染。此外,這一顯著簡化的模型系統(tǒng)將為高通量篩選抗cccDNA化合物提供更多的便利。
1.1 材料
大腸埃希菌ZYCY10P3S2T 購自SBI公司(MN920A-1)。人肝癌細(xì)胞株HepG2為本實驗室保存。prcccDNA質(zhì)粒為本實驗室構(gòu)建[7],編碼單拷貝的HBV基因組(ayw亞型,GenBank登錄號V01460.1)。微環(huán)母質(zhì)粒pMC為SBI公司產(chǎn)品(MN501A-1)。實驗所用的高保真DNA聚合酶PrimeSTAR和限制性內(nèi)切酶購自TaKaRa公司。C57BL/6雄性小鼠購自上海靈暢生物科技有限公司。
1.2 方法
1.2.1 質(zhì)粒構(gòu)建 以prcccDNA為模板,聚合酶鏈反應(yīng)(polymerase chain reaction,PCR)擴增HBV單拷貝基因組。引物序列分別為:F: 5′-GGGCGCGGCACCTATTGGTCTTACTGAC-3′; R:5′-ACGGTACCTTACCCCCAACTGAGAGA-ACTCAAAGGTTACCCCAGTTGGGGTATTGG-TCTCCTTAAACCTGTC-3′(斜體為KpnⅠ酶切位點,下劃線為反方向的位點特異性重組相關(guān)序列attP)。PCR產(chǎn)物經(jīng)KpnⅠ消化后連接到KpnⅠ/SmaⅠ雙酶切的微環(huán)母質(zhì)粒pMC中,獲得亞克隆質(zhì)粒prcccDNA-IV。pwtHBV1.2-intron質(zhì)粒編碼1.2拷貝的線性HBV基因組,attR雜合內(nèi)含子編碼序列(圖1)插入HBV表面抗原(HBV surface antigen,HBsAg)基因中相應(yīng)位置。
1.2.2 rcccDNA的體外誘導(dǎo)和制備 prcccDNA-IV常規(guī)轉(zhuǎn)化大腸埃希菌ZYCY10P3S2T。微環(huán)DNA的誘導(dǎo)和制備按廠商指導(dǎo)手冊進行,簡述如下:100 μL 新鮮培養(yǎng)的prcccDNA-IV轉(zhuǎn)化菌轉(zhuǎn)接入400 mL含有50 μg/mL卡那霉素的TB 培養(yǎng)基中,37 ℃振蕩培養(yǎng)16 h;加入400 mL LB培養(yǎng)液,16 mL 1 mol/L氫氧化鈉溶液及400 μL 20%L-阿拉伯糖,32 ℃繼續(xù)振蕩培養(yǎng)6 h;離心收集細(xì)菌沉淀,-80 ℃存儲備用。
The parental vector of rcccDNAattR(prcccDNA-IV) replicates in anE.colistrain ZYCY10P3S2T which harbors an arabinose-inducible system to express the PhiC31 integrase and the I-SceI endonuclease. PhiC31 recognizes two heterotypic sites (attBandattP) within prcccDNA-IV and catalyzes intramolecular recombination, thereby generating a rcccDNA minicircle containing anattR-chimeric intron (rcccDNAattR) and a minicircle of the plasmid backbone. The latter contains several engineered I-SceI restriction sites that ultimately leads to degradation. TheattR-chimeric intron is inserted within HBsAg gene. The exogenous insert should be removed from viral transcripts through RNA splicing.
圖1 體外誘導(dǎo)和制備rcccDNAattR的示意圖
Fig.1 Schematic of the induction of rcccDNAattRinvitro
1.2.3 rcccDNA的純化 采用去內(nèi)毒素的DNA純化試劑盒(Qiagen,12831)純化rcccDNA,離心收集細(xì)菌裂解液上清,避免物理切割超螺旋DNA。柱純化洗脫的DNA經(jīng)1%瓊脂糖凝膠電泳,切膠后分離具有超螺旋結(jié)構(gòu)的rcccDNA(約2.0 kb),用膠純化試劑盒(Qiagen,28704)回收純化。
1.2.4 細(xì)胞培養(yǎng)和轉(zhuǎn)染 HepG2細(xì)胞在含10%胎牛血清、100 U/mL青/鏈霉素的DMEM培養(yǎng)基(Gibco BRL)中常規(guī)培養(yǎng)。細(xì)胞轉(zhuǎn)染試劑采用Lipofectamine 2000(Invitrogen),轉(zhuǎn)染后4 d收取細(xì)胞上清液,檢測HBsAg和HBV e抗原(HBV e antigen,HBeAg)的表達。
1.2.5 酶聯(lián)免疫吸附試驗(enzyme-linked immunosorbent assay,ELISA)檢測 采用上??迫A生物工程股份有限公司的ELISA試劑盒,檢測細(xì)胞培養(yǎng)上清液中HBeAg和HBsAg的表達。用Benchmark ELISA酶標(biāo)儀(BioRad)讀取450 nm波長處光密度(optical density,OD)。調(diào)整樣品稀釋度,使OD450值為0.1~3.0。小鼠血清中HBsAg濃度用Abbott熒光定量PCR儀(于上海交通大學(xué)附屬瑞金醫(yī)院)測定。
1.2.6 DNA印跡檢測 參照文獻[7]進行。細(xì)胞裂解液用含1%十二烷基硫酸鈉(sodium dodecyl sulfate,SDS)的蛋白酶K(Merck)溶液(1 mg/mL)于55 ℃ 消化過夜,用酚/氯仿法抽提HBV DNA復(fù)制中間體。1%瓊脂糖凝膠電泳分離DNA,并轉(zhuǎn)移至Hybond-N+尼龍膜(Amersham)上。用地高辛標(biāo)記檢測試劑盒Ⅱ(Roche)標(biāo)記HBV特異性探針,用于DNA雜交。
1.2.7 小鼠尾靜脈高壓注射 參照文獻[7]進行。簡述如下:將4~5周齡C57BL/6雄性小鼠經(jīng)尾靜脈分別高壓注射 pwtHBV1.2-intron 質(zhì)粒2~8 μg或 rcccDNAattR2.4 μg,注射后每周從小鼠眼眶后靜脈叢采血,分離血清。
2.1 基于phiC31介導(dǎo)的位點特異性重組策略構(gòu)建rcccDNAattR
利用PhiC31 重組酶特異性識別attP和attB位點的特征,設(shè)計構(gòu)建含有單拷貝HBV基因組的微環(huán)母質(zhì)粒prcccDNA-IV(圖1)。在插入的微環(huán)母質(zhì)粒中,HBV基因組起始于HBsAg基因3′端(ayw亞型,nt203),結(jié)束于HBsAg基因5′端(nt202),上下游組成依次為34 bpattB、46 bp 3′內(nèi)含子序列、3 182 bp HBV單拷貝基因、41 bp 5′內(nèi)含子序列及39 bpattP序列。5′內(nèi)含子(供體序列)和3′內(nèi)含子(分支序列和受體序列)分別來自人類基因組的球蛋白基因和免疫球蛋白基因[7]。prcccDNA-IV在PhiC31作用下實現(xiàn)分子內(nèi)剪切,形成含有123 bpattR雜合內(nèi)含子的rcccDNA微環(huán)(rcccDNAattR)。與基于Cre/loxP重組系統(tǒng)構(gòu)建的rcccDNAloxP相似,attR雜合內(nèi)含子插于HBV基因組nt202與nt203之間,具有典型的外顯子邊界特征,能在病毒mRNA轉(zhuǎn)錄過程中被高效移除。母體質(zhì)粒骨架形成的微環(huán)DNA中含有質(zhì)粒復(fù)制元件及抗生素篩選基因,由于含有多個 I-SceⅠ酶切位點,在大腸埃希菌ZYCY10P3S2T中能被L-阿拉伯糖誘導(dǎo)表達的I-SceⅠ內(nèi)切酶剪切而降解。
2.2 體外誘導(dǎo)和純化具有超螺旋結(jié)構(gòu)的rcccDNAattR
ZYCY10P3S2T菌株中含有阿拉伯糖轉(zhuǎn)運蛋白基因LacY A177C,加入L-阿拉伯糖能誘導(dǎo)PhiC31重組酶和I-SceⅠ內(nèi)切酶的表達。Qiagen柱純化的rcccDNAattR微環(huán)在瓊脂糖凝膠電泳中顯示為約2.0 kb的條帶,與野生HBV cccDNA電泳條帶相似,提示具有相似的超螺旋結(jié)構(gòu)特征(圖2)。rcccDNAattR超螺旋能耐受95 ℃熱變性(10 min)[10],用HBV基因組特異限制性內(nèi)切酶EcoRⅠ處理后回復(fù)到3.2 kb,類似于HBV rcDNA的電泳特征。盡管如此,經(jīng)柱純化的rcccDNAattR產(chǎn)物并不理想,如圖2A所示,瓊脂糖凝膠電泳于2.0 kb超螺旋DNA之外仍可見很多污染物,可能包括宿主菌DNA片段、未重組的母體質(zhì)粒、母體質(zhì)粒骨架形成的微環(huán)DNA及含有多拷貝HBV基因組的DNA超螺旋,后者能耐受95 ℃熱變性和限制性內(nèi)切酶NdeⅠ的消化(NdeⅠ位點僅存在于微環(huán)母質(zhì)粒骨架結(jié)構(gòu)中,圖2B)。進一步應(yīng)用瓊脂糖凝膠回收方法,獲得單一條帶的rcccDNAattR(圖2C),這一純化方法簡便、高效,并不影響rcccDNAattR的超螺旋特征。瓊脂糖凝膠純化的rcccDNAattR通過DNA測序得到證實。
2.3 rcccDNAattR誘導(dǎo)功能性的病毒復(fù)制和抗原表達
HBsAg可指示rcccDNA的形成(圖1)。應(yīng)用純化的rcccDNAattR轉(zhuǎn)染肝腫瘤細(xì)胞系HepG2,在轉(zhuǎn)染后4 d的培養(yǎng)細(xì)胞上清液中檢測到HBeAg和HBsAg的表達(圖3A)。與rcccDNAloxP前體質(zhì)粒的轉(zhuǎn)染相似[7],應(yīng)用微環(huán)前體質(zhì)粒prcccDNA-IV轉(zhuǎn)染HepG2細(xì)胞僅能檢測到少量HBeAg的表達。另一方面,通過DNA印跡雜交法,在rcccDNAattR轉(zhuǎn)染的HepG2細(xì)胞中檢測到HBV特異的病毒復(fù)制中間體(圖3B)。這些結(jié)果表明,rcccDNAattR能誘導(dǎo)功能性的HBV復(fù)制和抗原表達。
2.4 尾靜脈高壓注射rcccDNAattR誘導(dǎo)小鼠模型中延長的抗原血癥
小鼠是理想的實驗?zāi)J絼游铮?但HBV并不感染小鼠[11];此外,由于未知原因,小鼠肝臟細(xì)胞中不能形成HBV cccDNA[12-13]。因此,本研究應(yīng)用尾靜脈高壓注射法[14-15]對rcccDNAattR誘導(dǎo)的HBV抗原血癥進行分析。如圖4所示,應(yīng)用1.2拷貝HBV基因組編碼質(zhì)粒(4 μg)注射免疫功能正常的C57BL/6小鼠,可檢測到血清中短暫的病毒抗原表達(通常在2周以內(nèi))。有意思的是,注射等摩爾比的rcccDNAattR(2.4 μg)可在小鼠模型中誘導(dǎo)出顯著延長的HBV抗原血癥(5~7周)。注射2 μg或4 μg rcccDNAattR均有類似的發(fā)現(xiàn)。以上結(jié)果提示,與普通的編碼線性HBV基因組的質(zhì)粒DNA相比,rcccDNAattR微環(huán)在體內(nèi)具有顯著的穩(wěn)定性。
A: DNA minicircles purified from theE.colistrain were heated to 95 ℃ for 10 min, with or without plasmid-safe (Pla) treatment as indicated at the bottom of each lane. B: After heat-denaturation, DNA minicircles were treated withEcoRI orNdeI. C: rcccDNAattRsupercoils (about 2.0 kb) were purified through gel extraction (QIAquick).
圖2 鑒定體外制備的rcccDNAattR
Fig.2 Identification of rcccDNAattRpreparedinvitro
A: ELISA assay of HBeAg and HBsAg in the medium of HepG2 cells 4 d after transfection with rcccDNAattR. pcDNA3.1 and the parental vector prcccDNA-IV were used as controls. B: Intracellular viral replication detected in HepG2 cells transfected with rcccDNAattRor prcccDNA-IV, by Southern blotting using HBV-specific probe. RC, relaxed circular form; DSL, double-stranded linear form; SS, single-stranded form.
圖3 rcccDNAattR誘導(dǎo)HepG2細(xì)胞中HBV抗原表達和病毒復(fù)制
Fig.3 rcccDNAattRinduces HBV antigen expression and viral replication in HepG2 cells
Kinetics of serum HBsAg at the indicated time points in C57BL/6 mice (4 weeks old, male;n=5) hydrodynamically injected with rcccDNAattR(2.4 μg). Mice injected with pwtHBV1.2-intron at indicated doses were set as controls. pwtHBV1.2-intron harbors 1.2-copy linear HBV genome with anattR-chimeric intron inserted into HBsAg gene. HBsAg was quantified using an architect platform (Abbott).
圖4 rcccDNAattR在免疫功能正常小鼠模型中誘導(dǎo)出延長的HBV抗原血癥
Fig.4 rcccDNAattRinduces prolonged HBV antigenemia in immunocompetent mice
HBV相關(guān)體內(nèi)外研究多采用線性化的病毒復(fù)制子系統(tǒng),即DNA質(zhì)?;蛑亟M病毒載體編碼部分重復(fù)或多拷貝串聯(lián)重復(fù)的HBV基因組[16],以替代cccDNA模板啟始病毒復(fù)制周期。然而,由于具有較大的基因組長度及攜帶大量的外源性片段(如原核特征的質(zhì)粒復(fù)制和抗性篩選元件等),DNA質(zhì)粒或重組病毒載體可能具有與3.2 kb HBV cccDNA顯著不同的病毒學(xué)特征和宿主反應(yīng)性。本課題組早期通過Cre/loxP介導(dǎo)的位點特異性重組策略,由前體質(zhì)粒誘導(dǎo)rcccDNAloxP產(chǎn)生[7],首次建立了HBV cccDNA的體外培養(yǎng)細(xì)胞和小鼠實驗?zāi)P?,因而獲得廣泛關(guān)注。
需指出的是,細(xì)胞核內(nèi)重組產(chǎn)生的rcccDNAloxP可能具有一些與HBV野生cccDNA不一致的特征。例如,Cre/loxP介導(dǎo)的位點特異性重組可能在表觀遺傳學(xué)水平影響rcccDNA微小染色體的重建,影響rcccDNAloxP在細(xì)胞核中的穩(wěn)定性。此外,rcccDNAloxP前體質(zhì)粒中的骨架結(jié)構(gòu)及共轉(zhuǎn)染的重組酶Cre編碼質(zhì)粒引入了大量原核生物特征元件,重組酶Cre的表達和DNA重組效率也明顯增加了系統(tǒng)復(fù)雜性。本研究通過設(shè)計基于PhiC31 重組酶介導(dǎo)的位點特異性重組,在大腸埃希菌系統(tǒng)(體外)誘導(dǎo)rcccDNAattR產(chǎn)生。rcccDNAattR直接轉(zhuǎn)染培養(yǎng)的細(xì)胞或通過尾靜脈高壓注射轉(zhuǎn)染小鼠肝細(xì)胞,有效避免了上述rcccDNAloxP系統(tǒng)的缺陷。
本研究沒有特別針對rcccDNAloxP與rcccDNAattR兩種系統(tǒng)的病毒學(xué)特征、體內(nèi)穩(wěn)定性等進行比較。上述兩種系統(tǒng)的雜合內(nèi)含子序列并不相同,rcccDNAattR在體外誘導(dǎo)和純化,而rcccDNAloxP在培養(yǎng)細(xì)胞系或?qū)嶒炐∈蟾渭?xì)胞核中由Cre重組酶介導(dǎo)的DNA重組形成。應(yīng)用rcccDNAloxP進行實驗對照時,須在系統(tǒng)中平行引入Cre表達質(zhì)粒,同時須考慮rcccDNAloxP重組效率及細(xì)胞核內(nèi)DNA重組對rcccDNA表觀遺傳學(xué)的影響等。
cccDNA是HBV慢性感染的分子基礎(chǔ)。與普通的線性HBV復(fù)制子編碼質(zhì)粒相比,直接應(yīng)用rcccDNAloxP尾靜脈高壓注射小鼠誘導(dǎo)了顯著延長的病毒抗原血癥,這一結(jié)果與本課題組早先基于rcccDNAloxP系統(tǒng)的研究類似。因此,(r)cccDNA的穩(wěn)定性是其內(nèi)在特征,與細(xì)胞核內(nèi)位點特異性重組及系統(tǒng)引入的非HBV DNA元件沒有顯著關(guān)聯(lián)。
總之,本研究是基于早期工作的改進,報道了一種體外誘導(dǎo)rcccDNA產(chǎn)生和純化的策略,在原核表達系統(tǒng)和實驗小鼠水平提供了一種更為簡化的實驗?zāi)P拖到y(tǒng),也將為高通量篩選抗cccDNA化合物提供更多的便利。
[1] Seeger C, Mason WS. Hepatitis B virus biology [J]. Microbiol Mol Biol Rev, 2000, 64(1): 51-68.
[2] Bock CT, Schwinn S, Locarnini S, Fyfe J, Manns MP, Trautwein C, Zentgraf H. Structural organization of the hepatitis B virus minichromosome [J]. J Mol Biol, 2001, 307(1): 183-196.
[3] Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones [J]. Gastroenterology, 2006, 130 (3): 823-837.
[4] Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, Litwin S, Furman PA, Jilbert AR, Mason WS. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis [J]. J Virol, 2001, 75(1): 311-322.
[5] Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B [J]. Gut, 2015, 64 (12): 1972-1984.
[6] Zoulim F, Lebossé F, Levrero M. Current treatments for chronic hepatitis B virus infections [J]. Curr Opin Virol, 2016, 18: 109-116.
[7] Qi Z, Li G, Hu H, Yang C, Zhang X, Leng Q, Xie Y, Yu D, Zhang X, Gao Y, Lan K, Deng Q. Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice [J]. J Virol, 2014, 88(14): 8045-8056.
[8] Thomson JG, Ow DW. Site-specific recombination systems for the genetic manipulation of eukaryotic genomes [J]. Genesis, 2006, 44(10): 465-476.
[9] Guo X, Chen P, Hou X, Xu W, Wang D, Wang TY, Zhang L, Zheng G, Gao ZL, He CY, Zhou B, Chen ZY. The recombined cccDNA produced using minicircle technology mimicked HBV genome in structure and function closely [J]. Sci Rep, 2016, 6: 25552.
[10] Gao W, Hu J. Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein [J]. J Virol, 2007, 81(12): 6164-6174.
[11] He W, Cao Z, Mao F, Ren B, Li Y, Li D, Li H, Peng B, Yan H, Qi Y, Sun Y, Wang F, Sui J, Li W. Modification of three amino acids in sodium taurocholate cotransporting polypeptide renders mice susceptible to infection with hepatitis D virus in vivo [J]. J Virol, 2016, 90(19): 8866-8874.
[12] Raney AK, Eggers CM, Kline EF, Guidotti LG, Pontoglio M, Yaniv M, McLachlan A. Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice [J]. J Virol, 2001, 75(6): 2900-2911.
[13] Lempp FA, Mutz P, Lipps C, Wirth D, Bartenschlager R, Urban S. Evidence that hepatitis B virus replication in mouse cells is limited by the lack of a host cell dependency factor [J]. J Hepatol, 2016, 64 (3): 556-564.
[14] Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection [J]. Proc Natl Acad Sci USA, 2002, 99(21): 13825-13830.
[15] Huang LR, Wu HL, Chen PJ, Chen DS. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection [J]. Proc Natl Acad Sci USA, 2006, 103(47): 17862-17867.
[16] Qin Y, Zhang J, Garcia T, Ito K, Gutelius D, Li J, Wands J, Tong S. Improved method for rapid and efficient determination of genome replication and protein expression of clinical hepatitis B virus isolates [J]. J Clin Microbiol, 2011, 49(4): 1226-1233.
s. GAO Yueqiu, E-mail: gaoyueqiu@hotmail.com;LI Gaiyun, E-mail: ligaiyun@ips.ac.cn
Preparing recombinant cccDNA of hepatitis B virusinvitrousing minicircle DNA vector technology
ZHU Yuanfei1, 2, LI Gaiyun2, CHANG Hao2, YU Kangkang2, GAO Yueqiu1, DENG Qiang1, 2
1.LaboratoryofCellularImmunity,ShuguangHospitalAffiliatedtoShanghaiUniversityofTraditionalChineseMedicine,Shanghai201203,China; 2.KeyLaboratoryofMolecularVirologyandImmunology,InstitutPasteurofShanghai,ChineseAcademyofSciences,Shanghai200032,China
Covalently closed circular DNA (cccDNA) of hepatitis B virus (HBV) is essential to establish and sustain viral replication. We recently reported a technique involving HBV recombinant cccDNA (rcccDNA) usingCre/loxP-mediated DNA recombination (rcccDNAloxP). rcccDNAloxPcould be substantially induced in the nuclei of hepatocytes, which thus represents a useful surrogate for HBV cccDNA-related investigations. In the present study, we described an approach to prepare rcccDNA in anEscherichiacoli(E.coli) strain ZYCY10P3S2T based on PhiC31-mediated site-specific recombination (rcccDNAattR). Purified rcccDNAattRminicircles were supercoils which demonstrated to support functional HBV expression and replication in the cell culture. Using the technique of hydrodynamic injection, rcccDNAattRinduced significantly prolonged HBV antigenemia in immunocompetent mice, as compared to a regular plasmid encoding linear HBV replicon. Collectively, our study provided a simplified method to surrogate HBV cccDNA in the prokaryotic expression system and in the mouse model. Our results suggested again that rcccDNA is intrinsically stable and could act as a prototype for modeling HBV persistence in mouse livers.
Minicircle DNA vector technology; PhiC31; Site-specific recombination; Hepatitis B virus; Covalently closed circular DNA
上海市科學(xué)技術(shù)委員會科研計劃項目(16401970600、17ZR1433400)
高月求,李改云
2017-02-28)